DGIdb - OPRELVEKIN Drug Record

OPRELVEKIN chembl:CHEMBL1201573 ApprovedAntineoplastic

Alternate Names:

OPRELVEKIN
NEUMEGA
AGIF
INTERLEUKIN-11 PRECURSOR
ADIPOGENESIS INHIBITORY FACTOR
IL-11
chembl:CHEMBL1201573
rxcui:139994
chemidplus:145941-26-0
drugbank:00038

Drug Info:

Drug Class	thrombotic
Year of Approval	1997
FDA Approval	approved
Drug Class	protein
Drug Indications	thrombopoietic

(2 More Sources)

Publications:

Nandurkar et al., 1996, The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor., Oncogene
Romas et al., 1996, The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures., J. Exp. Med.
Nandurkar et al., 1997, Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis., Blood
Li et al., 2001, Cloning of rat interleukin 11 and interleukin 11 receptor alpha chain and analysis of their expression in rat uterus in the peri-implantation period., Reproduction
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Nandurkar et al., 1998, The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor., Stem Cells
Yanagisawa et al., 2000, Astrocyte differentiation of fetal neuroepithelial cells by interleukin-11 via activation of a common cytokine signal transducer, gp130, and a transcription factor, STAT3., J. Neurochem.
Fuhrer et al., 1996, Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11., Exp. Hematol.
Suga et al., 2001, Interleukin-11 induces osteoblast differentiation and acts synergistically with bone morphogenetic protein-2 in C3H10T1/2 cells., J. Interferon Cytokine Res.
Kirkiles-Smith et al., 2004, IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression., J. Immunol.

OPRELVEKIN IL11RA

Interaction Score: 106.32

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name oprelvekin, YM 294, recombinant human interl/

Mechanism of Interaction Interleukin 11 receptor alpha agonist

PMIDs:
8637716 8676079 9310465 11570967 11752352 11012177

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
OPRELVEKIN MYOD1

Interaction Score: 2.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11576464

Sources:
NCI
OPRELVEKIN GFAP

Interaction Score: 0.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10737606

Sources:
NCI
OPRELVEKIN BIRC5

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14734714

Sources:
NCI
OPRELVEKIN PIK3CG

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8641341

Sources:
NCI
OPRELVEKIN PIK3CA

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8641341

Sources:
NCI

TEND: OPRELVEKIN
- Version: 01-August-2011
Alternate Names:

OPRELVEKIN Primary Drug Name

Drug Info:

Year of Approval 1997

Drug Class thrombotic

Publications:
TdgClinicalTrial: OPRELVEKIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications thrombopoietic

Drug Class protein

FDA Approval approved

Publications:

NCI: IL-11

Version: 14-September-2017

Alternate Names:

C1303 NCI drug code

Drug Info:

Publications:

Kirkiles-Smith et al., 2004, IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression., J. Immunol.

Yanagisawa et al., 2000, Astrocyte differentiation of fetal neuroepithelial cells by interleukin-11 via activation of a common cytokine signal transducer, gp130, and a transcription factor, STAT3., J. Neurochem.

Fuhrer et al., 1996, Activation of Src-family protein tyrosine kinases and phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by interleukin-11., Exp. Hematol.

TTD: Oprelvekin
- Version: 2020.06.01
Alternate Names:

D0T1IJ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201573
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201573
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	oprelvekin, YM 294, recombinant human interl/
Mechanism of Interaction	Interleukin 11 receptor alpha agonist

OPRELVEKIN Drug Record

OPRELVEKIN chembl:CHEMBL1201573 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

OPRELVEKIN IL11RA

Interaction Types & Directionality: agonist (activating)

Interaction Info: Novel drug target Established target Trial Name oprelvekin, YM 294, recombinant human interl/ Mechanism of Interaction Interleukin 11 receptor alpha agonist

PMIDs: 8637716 8676079 9310465 11570967 11752352 11012177

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

OPRELVEKIN MYOD1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11576464

Sources: NCI

OPRELVEKIN GFAP

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10737606

Sources: NCI

OPRELVEKIN BIRC5

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14734714

Sources: NCI

OPRELVEKIN PIK3CG

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8641341

Sources: NCI

OPRELVEKIN PIK3CA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8641341

Sources: NCI

TEND: OPRELVEKIN

Alternate Names: OPRELVEKIN Primary Drug Name

Drug Info: Year of Approval 1997 Drug Class thrombotic

Publications:

TdgClinicalTrial: OPRELVEKIN

Alternate Names:

Drug Info: Drug Indications thrombopoietic Drug Class protein FDA Approval approved

Publications:

NCI: IL-11

Alternate Names: C1303 NCI drug code

Drug Info:

TTD: Oprelvekin

Alternate Names: D0T1IJ TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201573

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201573

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name oprelvekin, YM 294, recombinant human interl/

Mechanism of Interaction Interleukin 11 receptor alpha agonist

PMIDs:
8637716 8676079 9310465 11570967 11752352 11012177

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
11576464

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10737606

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14734714

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8641341

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8641341

Sources:
NCI

Alternate Names:

OPRELVEKIN Primary Drug Name

Drug Info:

Year of Approval 1997

Drug Class thrombotic

Drug Info:

Drug Indications thrombopoietic

Drug Class protein

FDA Approval approved

Alternate Names:

C1303 NCI drug code

Alternate Names:

D0T1IJ TTD Drug ID